June 26, 2014 -- Verisante Technology of Canada sold China rights for its Core ™ cancer diagnostic device, a laser Raman Spectroscopy (LRS) system, to an unnamed partner. The partner will make a $300,000 private placement in Verisante and be responsible for China registration, including a China clinical trial, if necessary. To close the deal, Verisante must raise an additional $2.5 million before the end of September.
Help employers find you! Check out all the jobs and post your resume.
